IDEAS home Printed from https://ideas.repec.org/a/spr/scient/v125y2020i3d10.1007_s11192-020-03707-y.html
   My bibliography  Save this article

Innovation in pharmaceutical R&D: mapping the research landscape

Author

Listed:
  • Angelo Kenneth S. Romasanta

    () (Vrije Universiteit Amsterdam
    Vrije Universiteit Amsterdam)

  • Peter Sijde

    (Vrije Universiteit Amsterdam)

  • Jacqueline Muijlwijk-Koezen

    (Vrije Universiteit Amsterdam)

Abstract

In response to the increasing number and breadth of innovation studies on the pharmaceutical industry, we mapped the literature to show the trends in recent research and to indicate areas for further research. In the first phase, we analyzed articles on the pharmaceutical industry published in innovation journals. We used these articles’ textual and citation data and applied hybrid cluster analysis. Three main clusters were produced based on the level of analysis innovation scholars had used to investigate the industry: macro, meso and micro. We describe the research topics within these clusters and show that, overall, innovation scholars increasingly focus on the meso-level, analyzing the relationships across different firms. This shift in interest toward the collaborative nature of drug discovery and development was also apparent in macro- and micro-level studies. To explore how this literature is used by scientists in the industry, our second phase involved analysis of the citing articles published in pharmaceutical journals. Using our findings, we propose research areas that can be further explored in order to create an engaged and better-integrated literature on pharmaceutical innovation.

Suggested Citation

  • Angelo Kenneth S. Romasanta & Peter Sijde & Jacqueline Muijlwijk-Koezen, 2020. "Innovation in pharmaceutical R&D: mapping the research landscape," Scientometrics, Springer;Akadémiai Kiadó, vol. 125(3), pages 1801-1832, December.
  • Handle: RePEc:spr:scient:v:125:y:2020:i:3:d:10.1007_s11192-020-03707-y
    DOI: 10.1007/s11192-020-03707-y
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s11192-020-03707-y
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. James G. March, 1991. "Exploration and Exploitation in Organizational Learning," Organization Science, INFORMS, vol. 2(1), pages 71-87, February.
    2. Gary P. Pisano, 1994. "Knowledge, Integration, and the Locus of Learning: An Empirical Analysis of Process Development," Strategic Management Journal, Wiley Blackwell, vol. 15(S1), pages 85-100, December.
    3. Mary M. Crossan & Marina Apaydin, 2010. "A Multi‐Dimensional Framework of Organizational Innovation: A Systematic Review of the Literature," Journal of Management Studies, Wiley Blackwell, vol. 47(6), pages 1154-1191, September.
    4. Lemus, Jorge & Marshall, Guillermo, 2018. "When the clock starts ticking: Measuring strategic responses to TRIPS's patent term change," Research Policy, Elsevier, vol. 47(4), pages 796-804.
    5. Samira Guennif & Shyama Ramani, 2012. "Explaining divergence in catching-up in pharmaceuticals between India and Brazil using the National System Innovation framework," Post-Print hal-01345868, HAL.
    6. DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016. "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, vol. 47(C), pages 20-33.
    7. Rzakhanov, Zaur, 2008. "Regulatory policy, value of knowledge assets and innovation strategy: The case of the Orphan Drug Act," Research Policy, Elsevier, vol. 37(4), pages 673-689, May.
    8. Henry Grabowski, 2002. "Patents, Innovation and Access to New Pharmaceuticals," Journal of International Economic Law, Oxford University Press, vol. 5(4), pages 849-860, December.
    9. Kuemmerle, Walter, 1999. "Foreign direct investment in industrial research in the pharmaceutical and electronics industries--results from a survey of multinational firms," Research Policy, Elsevier, vol. 28(2-3), pages 179-193, March.
    10. Manuel Trajtenberg, 1990. "A Penny for Your Quotes: Patent Citations and the Value of Innovations," RAND Journal of Economics, The RAND Corporation, vol. 21(1), pages 172-187, Spring.
    11. Hopkins, Michael M. & Martin, Paul A. & Nightingale, Paul & Kraft, Alison & Mahdi, Surya, 2007. "The myth of the biotech revolution: An assessment of technological, clinical and organisational change," Research Policy, Elsevier, vol. 36(4), pages 566-589, May.
    12. Gopesh Anand & John Gray & Enno Siemsen, 2012. "Decay, Shock, and Renewal: Operational Routines and Process Entropy in the Pharmaceutical Industry," Organization Science, INFORMS, vol. 23(6), pages 1700-1716, December.
    13. Casper, Steven & Matraves, Catherine, 2003. "Institutional frameworks and innovation in the German and UK pharmaceutical industry," Research Policy, Elsevier, vol. 32(10), pages 1865-1879, December.
    14. Carlsson, Bo & Jacobsson, Staffan & Holmen, Magnus & Rickne, Annika, 2002. "Innovation systems: analytical and methodological issues," Research Policy, Elsevier, vol. 31(2), pages 233-245, February.
    15. Grabowski, Henry, 2002. "Patents, Innovation and Access to New Pharmaceuticals," Working Papers 02-28, Duke University, Department of Economics.
    16. Pelin Demirel & Mariana Mazzucato, 2012. "Innovation and Firm Growth: Is R&D Worth It?," Industry and Innovation, Taylor & Francis Journals, vol. 19(1), pages 45-62, January.
    17. Peter Moran, 2005. "Structural vs. relational embeddedness: social capital and managerial performance," Strategic Management Journal, Wiley Blackwell, vol. 26(12), pages 1129-1151, December.
    18. Bronwyn H. Hall & Adam Jaffe & Manuel Trajtenberg, 2005. "Market Value and Patent Citations," RAND Journal of Economics, The RAND Corporation, vol. 36(1), pages 16-38, Spring.
    19. Gilsing, Victor & Nooteboom, Bart & Vanhaverbeke, Wim & Duysters, Geert & van den Oord, Ad, 2008. "Network embeddedness and the exploration of novel technologies: Technological distance, betweenness centrality and density," Research Policy, Elsevier, vol. 37(10), pages 1717-1731, December.
    20. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G. & Lasagna, Louis, 1991. "Cost of innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 10(2), pages 107-142, July.
    21. Suma Athreye & Dinar Kale & Shyama V. Ramani, 2009. "Experimentation with strategy and the evolution of dynamic capability in the Indian pharmaceutical sector," Industrial and Corporate Change, Oxford University Press, vol. 18(4), pages 729-759, August.
    22. Srikanth Paruchuri, 2010. "Intraorganizational Networks, Interorganizational Networks, and the Impact of Central Inventors: A Longitudinal Study of Pharmaceutical Firms," Organization Science, INFORMS, vol. 21(1), pages 63-80, February.
    23. Wesley M. Cohen & Richard R. Nelson & John P. Walsh, 2000. "Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not)," NBER Working Papers 7552, National Bureau of Economic Research, Inc.
    24. Gilsing, Victor & Nooteboom, Bart, 2006. "Exploration and exploitation in innovation systems: The case of pharmaceutical biotechnology," Research Policy, Elsevier, vol. 35(1), pages 1-23, February.
    25. John Hagedoorn, 1993. "Understanding the rationale of strategic technology partnering: Interorganizational modes of cooperation and sectoral differences," Strategic Management Journal, Wiley Blackwell, vol. 14(5), pages 371-385, July.
    26. Tierney, Robert & Hermina, Wahid & Walsh, Steven, 2013. "The pharmaceutical technology landscape: A new form of technology roadmapping," Technological Forecasting and Social Change, Elsevier, vol. 80(2), pages 194-211.
    27. McMillan, G. Steven & Narin, Francis & Deeds, David L., 2000. "An analysis of the critical role of public science in innovation: the case of biotechnology," Research Policy, Elsevier, vol. 29(1), pages 1-8, January.
    28. Zucker, Lynne G. & Darby, Michael R., 1997. "Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm," Research Policy, Elsevier, vol. 26(4-5), pages 429-446, December.
    29. Nees Jan Eck & Ludo Waltman, 2010. "Software survey: VOSviewer, a computer program for bibliometric mapping," Scientometrics, Springer;Akadémiai Kiadó, vol. 84(2), pages 523-538, August.
    30. Harhoff, Dietmar & Scherer, Frederic M. & Vopel, Katrin, 2003. "Citations, family size, opposition and the value of patent rights," Research Policy, Elsevier, vol. 32(8), pages 1343-1363, September.
    31. Peter J. Lane & Michael Lubatkin, 1998. "Relative absorptive capacity and interorganizational learning," Post-Print hal-02311860, HAL.
    32. Frank T. Rothaermel & Warren Boeker, 2008. "Old technology meets new technology: complementarities, similarities, and alliance formation," Strategic Management Journal, Wiley Blackwell, vol. 29(1), pages 47-77, January.
    33. Orsenigo, L. & Pammolli, F. & Riccaboni, Massimo, 2001. "Technological change and network dynamics: Lessons from the pharmaceutical industry," Research Policy, Elsevier, vol. 30(3), pages 485-508, March.
    34. Rebecca Henderson & Iain Cockburn, 1994. "Measuring Competence? Exploring Firm Effects in Pharmaceutical Research," Strategic Management Journal, Wiley Blackwell, vol. 15(S1), pages 63-84, December.
    35. Henrik Bresman & Mary Zellmer-Bruhn, 2013. "The Structural Context of Team Learning: Effects of Organizational and Team Structure on Internal and External Learning," Organization Science, INFORMS, vol. 24(4), pages 1120-1139, August.
    36. Konstantinos Grigoriou & Frank T. Rothaermel, 2017. "Organizing for knowledge generation: internal knowledge networks and the contingent effect of external knowledge sourcing," Strategic Management Journal, Wiley Blackwell, vol. 38(2), pages 395-414, February.
    37. Dong, John Qi & Yang, Chia-Han, 2016. "Being central is a double-edged sword: Knowledge network centrality and new product development in U.S. pharmaceutical industry," Technological Forecasting and Social Change, Elsevier, vol. 113(PB), pages 379-385.
    38. Edwin Mansfield, 1986. "Patents and Innovation: An Empirical Study," Management Science, INFORMS, vol. 32(2), pages 173-181, February.
    39. Ingemar Dierickx & Karel Cool, 1989. "Asset Stock Accumulation and the Sustainability of Competitive Advantage: Reply," Management Science, INFORMS, vol. 35(12), pages 1514-1514, December.
    40. Frank T. Rothaermel & David L. Deeds, 2004. "Exploration and exploitation alliances in biotechnology: a system of new product development," Strategic Management Journal, Wiley Blackwell, vol. 25(3), pages 201-221, March.
    41. Stuart, Toby E. & Ozdemir, Salih Zeki & Ding, Waverly W., 2007. "Vertical alliance networks: The case of university-biotechnology-pharmaceutical alliance chains," Research Policy, Elsevier, vol. 36(4), pages 477-498, May.
    42. Henrik Bresman, 2010. "External Learning Activities and Team Performance: A Multimethod Field Study," Organization Science, INFORMS, vol. 21(1), pages 81-96, February.
    43. Qiang Liu & Sachin Gupta & Sriram Venkataraman & Hongju Liu, 2016. "An Empirical Model of Drug Detailing: Dynamic Competition and Policy Implications," Management Science, INFORMS, vol. 62(8), pages 2321-2340, August.
    44. Frank T. Rothaermel, 2001. "Incumbent's advantage through exploiting complementary assets via interfirm cooperation," Strategic Management Journal, Wiley Blackwell, vol. 22(6‐7), pages 687-699, June.
    45. Arundel, Anthony & Kabla, Isabelle, 1998. "What percentage of innovations are patented? empirical estimates for European firms," Research Policy, Elsevier, vol. 27(2), pages 127-141, June.
    46. Franco Malerba & Luigi Orsenigo, 2015. "The evolution of the pharmaceutical industry," Business History, Taylor & Francis Journals, vol. 57(5), pages 664-687, July.
    47. Ingemar Dierickx & Karel Cool, 1989. "Asset Stock Accumulation and Sustainability of Competitive Advantage," Management Science, INFORMS, vol. 35(12), pages 1504-1511, December.
    48. Waltman, Ludo & van Eck, Nees Jan & Noyons, Ed C.M., 2010. "A unified approach to mapping and clustering of bibliometric networks," Journal of Informetrics, Elsevier, vol. 4(4), pages 629-635.
    49. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
    50. Henry Grabowski & John Vernon, 1990. "A New Look at the Returns and Risks to Pharmaceutical R&D," Management Science, INFORMS, vol. 36(7), pages 804-821, July.
    51. Achilladelis, Basil & Antonakis, Nicholas, 2001. "The dynamics of technological innovation: the case of the pharmaceutical industry," Research Policy, Elsevier, vol. 30(4), pages 535-588, April.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Bruce Rasmussen, 2010. "Innovation and Commercialisation in the Biopharmaceutical Industry," Books, Edward Elgar Publishing, number 13680.
    2. Tammy L. Madsen & Michael J. Leiblein, 2015. "What Factors Affect the Persistence of an Innovation Advantage?," Journal of Management Studies, Wiley Blackwell, vol. 52(8), pages 1097-1127, December.
    3. Bart Leten & Rene Belderbos & Bart Van Looy, 2016. "Entry and Technological Performance in New Technology Domains: Technological Opportunities, Technology Competition and Technological Relatedness," Journal of Management Studies, Wiley Blackwell, vol. 53(8), pages 1257-1291, December.
    4. Jaeho Kim & Andy Wu, 2019. "Extending the role of headquarters beyond the firm boundary: entrepreneurial alliance innovation," Journal of Organization Design, Springer;Organizational Design Community, vol. 8(1), pages 1-35, December.
    5. Guan, Jiancheng & Liu, Na, 2016. "Exploitative and exploratory innovations in knowledge network and collaboration network: A patent analysis in the technological field of nano-energy," Research Policy, Elsevier, vol. 45(1), pages 97-112.
    6. Lampert, Curba Morris & Kim, Minyoung, 2019. "Going far to go further: Offshoring, exploration, and R&D performance," Journal of Business Research, Elsevier, vol. 103(C), pages 376-386.
    7. Armin Anzenbacher & Marcus Wagner, 2020. "The role of exploration and exploitation for innovation success: effects of business models on organizational ambidexterity in the semiconductor industry," International Entrepreneurship and Management Journal, Springer, vol. 16(2), pages 571-594, June.
    8. Maria Chiara Di Guardo & Kathryn Rudie Harrigan & Elona Marku, 2019. "M&A and diversification strategies: what effect on quality of inventive activity?," Journal of Management & Governance, Springer;Accademia Italiana di Economia Aziendale (AIDEA), vol. 23(3), pages 669-692, September.
    9. Deepak Somaya & Ian O. Williamson & Xiaomeng Zhang, 2007. "Combining Patent Law Expertise with R&D for Patenting Performance," Organization Science, INFORMS, vol. 18(6), pages 922-937, December.
    10. Gamba, Simona, 2017. "The Effect of Intellectual Property Rights on Domestic Innovation in the Pharmaceutical Sector," World Development, Elsevier, vol. 99(C), pages 15-27.
    11. Vikas A. Aggarwal, 2020. "Resource congestion in alliance networks: How a firm's partners’ partners influence the benefits of collaboration," Strategic Management Journal, Wiley Blackwell, vol. 41(4), pages 627-655, April.
    12. Francesco Paolo Appio & Fabrizio Cesaroni & Alberto Minin, 2014. "Visualizing the structure and bridges of the intellectual property management and strategy literature: a document co-citation analysis," Scientometrics, Springer;Akadémiai Kiadó, vol. 101(1), pages 623-661, October.
    13. Zhili Tian & Ralph Siebert, 2020. "Dynamic Effects of Licensing and Knowledge Transfer across Research Stages: Evidence from the Pharmaceutical Industry," CESifo Working Paper Series 8311, CESifo.
    14. Shukla, Dhirendra Mani & Mital, Amita & Qureshi, Israr & Wang, Taiyuan, 2020. "Valuation effects of alliance portfolio expansion speed and strength: Evidence from high-tech firms," Journal of Business Research, Elsevier, vol. 113(C), pages 370-383.
    15. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    16. Alessia Pisoni & Alberto Onetti & Luciano Fratocchi & Marco Talaia, 2010. "Managing R&D activities in the Italian red biotech industry. A comparison between Italian independent firms and multinational companies," Economics and Quantitative Methods qf1003, Department of Economics, University of Insubria.
    17. Rene Belderbos & Victor Gilsing & Shinya Suzuki, 2015. "Direct and mediated ties to universities: ‘Scientific’ absorptive capacity and innovation performance of pharmaceutical firms," Working Papers of Department of Management, Strategy and Innovation, Leuven 504836, KU Leuven, Faculty of Economics and Business (FEB), Department of Management, Strategy and Innovation, Leuven.
    18. Nicolas van Zeebroeck & Bruno van Pottelsberghe de la Potterie, 2011. "Filing strategies and patent value," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 20(6), pages 539-561, February.
    19. Martin Kalthaus, 2020. "Knowledge recombination along the technology life cycle," Journal of Evolutionary Economics, Springer, vol. 30(3), pages 643-704, July.
    20. Sears, Joshua B., 2018. "Post-acquisition integrative versus independent innovation: A story of dueling success factors," Research Policy, Elsevier, vol. 47(9), pages 1688-1699.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:scient:v:125:y:2020:i:3:d:10.1007_s11192-020-03707-y. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Sonal Shukla) or (Springer Nature Abstracting and Indexing). General contact details of provider: http://www.springer.com .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.